Reuters logo
in 22 days
BRIEF-Ziopharm Oncology announces initiation of stereotactic treatment cohort in phase 1 study of Ad-RTS-hIL-12 + veledimex in recurrent glioblastoma
June 28, 2017 / 11:13 AM / in 22 days

BRIEF-Ziopharm Oncology announces initiation of stereotactic treatment cohort in phase 1 study of Ad-RTS-hIL-12 + veledimex in recurrent glioblastoma

1 Min Read

June 28 (Reuters) - Ziopharm Oncology Inc

* Ziopharm Oncology announces initiation of stereotactic treatment cohort in phase 1 study of Ad-RTS-hIL-12 + veledimex in recurrent glioblastoma

* Ziopharm Oncology Inc - ‍company anticipates children with diffuse intrinsic pontine glioma (dipg) will be eligible for enrollment​

* Ziopharm Oncology Inc - ‍continues to progress towards a registration study for Ad-RTS-hIL-12 + veledimex for rGBM to start in 2017​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below